Novartis announced that investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and ...
Please provide your email address to receive an email when new articles are posted on . Mometasone furoate, indacaterol acetate and glycopyrronium bromide improved lung function and reduced ...
Novartis announced the first study results from the phase III PLATINUM clinical development programme assessing the safety and efficacy of QMF149, an investigational, once-daily, fixed dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results